At Karma Oncology we are committed to helping our clients advance their oncology programs to the next stage.
Pioneering early stage companies leverage our experienced panel of clinical development experts to develop best-in-class Clinical Development Plans to attract the right investors and optimise the clinical and regulatory strategy.
Clinical stage companies come to us for our operational excellence and then stay with us for our industry leading quality and low-overhead pricing. We understand that experience, speed and excellent site relationships are the key to effective clinical study delivery. And with Karma, you get the same team from start-to-finish, not only because we have among the lowest staff turnover in the business (<5% annually), but because we do not have a start up team and a monitoring team, it is all one team delivered by our career CRAs who provide continuity and expertise.
Our expertise is in solid tumours and haematological malignancies and spans a multitude of therapeutic approaches including autologous and CAR-T cell therapies. While oncology is in our name, we do also have experience in many other indications and our sister company, Karma Cardiology provides the same services for cardiology and cardiovascular disease.